AMGN vs PFE — Key Metrics
| Metric | AMGN (AMGEN INC) | PFE (PFIZER INC) |
|---|---|---|
| Price | 443.89 | 28.06 |
| Market Cap | 240.11 Billion | 159.94 Billion |
| P/E (TTM) | 25.54 | 39.52 |
| P/B (Quarterly) | 18.033 | 1.921 |
| P/S (TTM) | 6.17 | 2.51 |
| Net Profit Margin (TTM) | 24.1 | 6.3 |
| Gross Margin (TTM) | 70.9 | 73.4 |
| ROE (TTM) | 85.6 | 4.6 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Outperform
Greatly Outperform
Recommendation Summary
Stock AMGN is projected to outperform the market, stock PFE is projected to greatly outperform the market. Upfront Recommendation: PFE.
Financial Metrics
| AMGN | Metrics | PFE |
|---|---|---|
| $443.89 | Price | $28.06 |
| — | Market Capitalization | — |
| 25.54 | Price to Earnings Ratio | 39.52 |
| 6.17 | Price to Sales | 2.51 |
| 25.06 | Price to FCF Ratio | 13.57 |
| 8.7 | Price to Gross Profit | 3.43 |
| 30.63 | Price to R&D | 13.88 |
| 6.99 | Price to Current Assets | 3.55 |
AMGN vs PFE at a glance
Amgen INC (AMGN) and Pfizer INC (PFE) are both Drug Manufacturers - General companies in the Healthcare sector. AMGN is the larger, at $240.1 billion in market value against $159.9 billion for PFE, about 1.5 times the size.
On trailing-twelve-month figures, AMGN trades at 25.5 times trailing earnings and PFE at 39.5; net profit margins are 24.1% and 6.3%.
The Upfront Investment model currently rates AMGN Outperform and PFE Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.